Pfizer ’s Besponsa gets FDA approval for treatment of B-cell precursor ALL

The US Food and Drug Administration has given approval for Pfizer ’s Besponsa (inotuzumab ozogamicin) to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news